300 related articles for article (PubMed ID: 28515105)
1. Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort Study.
Schröck A; Leisse A; de Vos L; Gevensleben H; Dröge F; Franzen A; Wachendörfer M; Schröck F; Ellinger J; Teschke M; Wilhelm-Buchstab T; Landsberg J; Holdenrieder S; Hartmann G; Field JK; Bootz F; Kristiansen G; Dietrich D
Clin Chem; 2017 Jul; 63(7):1288-1296. PubMed ID: 28515105
[TBL] [Abstract][Full Text] [Related]
2. Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients.
de Vos L; Gevensleben H; Schröck A; Franzen A; Kristiansen G; Bootz F; Dietrich D
Clin Epigenetics; 2017; 9():125. PubMed ID: 29213339
[TBL] [Abstract][Full Text] [Related]
3. Circulating Cell-Free SEPT9 DNA Methylation in Blood Is a Biomarker for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma Patients.
Dietrich D; Weider S; de Vos L; Vogt TJ; Färber M; Zarbl R; Hunecke A; Glosch AK; Gabrielpillai J; Bootz F; Bauernfeind FG; Kramer FJ; Kristiansen G; Brossart P; Strieth S; Franzen A
Clin Chem; 2023 Sep; 69(9):1050-1061. PubMed ID: 37477541
[TBL] [Abstract][Full Text] [Related]
4. Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study.
Bergheim J; Semaan A; Gevensleben H; Groening S; Knoblich A; Dietrich J; Weber J; Kalff JC; Bootz F; Kristiansen G; Dietrich D
Br J Cancer; 2018 May; 118(9):1217-1228. PubMed ID: 29610456
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of DNA methylation levels of
Grossi I; Assoni C; Lorini L; Smussi D; Gurizzan C; Grisanti S; Paderno A; Mattavelli D; Piazza C; Pelisenco IA; De Petro G; Salvi A; Bossi P
Oncol Rep; 2024 Mar; 51(3):. PubMed ID: 38299234
[TBL] [Abstract][Full Text] [Related]
6. Treatment Response Monitoring in Patients with Advanced Malignancies Using Cell-Free SHOX2 and SEPT9 DNA Methylation in Blood: An Observational Prospective Study.
de Vos L; Jung M; Koerber RM; Bawden EG; Holderried TAW; Dietrich J; Bootz F; Brossart P; Kristiansen G; Dietrich D
J Mol Diagn; 2020 Jul; 22(7):920-933. PubMed ID: 32361006
[TBL] [Abstract][Full Text] [Related]
7. Promoter hypermethylation of
Branchi V; Schaefer P; Semaan A; Kania A; Lingohr P; Kalff JC; Schäfer N; Kristiansen G; Dietrich D; Matthaei H
Clin Epigenetics; 2016; 8():133. PubMed ID: 27999621
[TBL] [Abstract][Full Text] [Related]
8.
Sailer V; Holmes EE; Gevensleben H; Goltz D; Dröge F; Franzen A; Dietrich J; Kristiansen G; Bootz F; Schröck A; Dietrich D
Clin Epigenetics; 2017; 9():12. PubMed ID: 28174607
[TBL] [Abstract][Full Text] [Related]
9. Cell-Free
Jung M; Ellinger J; Gevensleben H; Syring I; Lüders C; de Vos L; Pützer S; Bootz F; Landsberg J; Kristiansen G; Dietrich D
Clin Chem; 2019 Apr; 65(4):559-568. PubMed ID: 30626634
[TBL] [Abstract][Full Text] [Related]
10. PITX2 and PANCR DNA methylation predicts overall survival in patients with head and neck squamous cell carcinoma.
Sailer V; Holmes EE; Gevensleben H; Goltz D; Dröge F; de Vos L; Franzen A; Schröck F; Bootz F; Kristiansen G; Schröck A; Dietrich D
Oncotarget; 2016 Nov; 7(46):75827-75838. PubMed ID: 27716615
[TBL] [Abstract][Full Text] [Related]
11. Intragenic DNA methylation of PITX1 and the adjacent long non-coding RNA C5orf66-AS1 are prognostic biomarkers in patients with head and neck squamous cell carcinomas.
Sailer V; Charpentier A; Dietrich J; Vogt TJ; Franzen A; Bootz F; Dietrich D; Schroeck A
PLoS One; 2018; 13(2):e0192742. PubMed ID: 29425237
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic and predictive methylation biomarkers in HNSCC : Epigenomic diagnostics for head and neck squamous cell carcinoma (HNSCC)].
Franzen A; Bootz F; Dietrich D
HNO; 2020 Dec; 68(12):911-915. PubMed ID: 32613323
[TBL] [Abstract][Full Text] [Related]
13. NDN and CD1A are novel prognostic methylation markers in patients with head and neck squamous carcinomas.
Virani S; Bellile E; Bradford CR; Carey TE; Chepeha DB; Colacino JA; Helman JI; McHugh JB; Peterson LA; Sartor MA; Taylor JM; Walline HM; Wolf GT; Rozek LS
BMC Cancer; 2015 Oct; 15():825. PubMed ID: 26518708
[TBL] [Abstract][Full Text] [Related]
14. Postoperative serum methylation levels of TAC1 and SEPT9 are independent predictors of recurrence and survival of patients with colorectal cancer.
Tham C; Chew M; Soong R; Lim J; Ang M; Tang C; Zhao Y; Ong SY; Liu Y
Cancer; 2014 Oct; 120(20):3131-41. PubMed ID: 24925595
[TBL] [Abstract][Full Text] [Related]
15. Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease.
Weiss G; Schlegel A; Kottwitz D; König T; Tetzner R
J Thorac Oncol; 2017 Jan; 12(1):77-84. PubMed ID: 27544059
[TBL] [Abstract][Full Text] [Related]
16. Correlation of gene methylation in surgical margin imprints with locoregional recurrence in head and neck squamous cell carcinoma.
Hayashi M; Wu G; Roh JL; Chang X; Li X; Ahn J; Goldsmith M; Khan Z; Bishop J; Zhang Z; Zhou XC; Richmon J; Agrawal N; Koch WM
Cancer; 2015 Jun; 121(12):1957-65. PubMed ID: 25773145
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of circulating biomarker score in advanced-stage head and neck squamous cell carcinoma.
Park MJ; Roh JL; Kim SB; Choi SH; Nam SY; Kim SY
Eur J Cancer; 2018 Mar; 92():69-76. PubMed ID: 29428866
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites.
Jung M; Pützer S; Gevensleben H; Meller S; Kristiansen G; Dietrich D
Clin Epigenetics; 2016; 8():24. PubMed ID: 26937257
[TBL] [Abstract][Full Text] [Related]
19. The Association and Clinical Significance of CDKN2A Promoter Methylation in Head and Neck Squamous Cell Carcinoma: a Meta-Analysis.
Zhou C; Shen Z; Ye D; Li Q; Deng H; Liu H; Li J
Cell Physiol Biochem; 2018; 50(3):868-882. PubMed ID: 30355925
[TBL] [Abstract][Full Text] [Related]
20. Liquid biopsy: An emerging prognostic and predictive tool in Head and Neck Squamous Cell Carcinoma (HNSCC). Focus on Circulating Tumor Cells (CTCs).
Economopoulou P; Kotsantis I; Kyrodimos E; Lianidou ES; Psyrri A
Oral Oncol; 2017 Nov; 74():83-89. PubMed ID: 29103757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
